Navigation Links
Coherus Announces CHS-1420 (Investigational Adalimumab Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
Date:8/14/2014

REDWOOD CITY, Calif., Aug. 14, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. ("Coherus") today announced that CHS-1420, its proposed biosimilar of adalimumab (Humira®), met the primary endpoint in a pivotal clinical pharmacokinetic (PK) similarity study that compared CHS-1420 to Humira® in healthy subjects.  The parallel-group, single-dose study met the criteria for clinical PK similarity on all three required, prospectively defined, PK endpoints: maximum serum concentration (Cmax), area under the time-concentration curve from first to last time point measured (AUC0-t), and area under the time-concentration curve from first time point extrapolated to infinity (AUC0-inf), with all three geometric mean ratios fully within the 90% confidence interval from 80% to 125%.  Both agents were well tolerated and there were no differential safety findings observed between the two agents in this study.

"An essential global regulatory requirement is the completion of a clinical study directly comparing the originator and our biosimilar candidate establishing PK similarity," said Barbara Finck, M.D., Chief Medical Officer of Coherus. "We are pleased to have achieved robust results which we believe represents a significant reduction in development program risk."

"Adalimumab is a very complex molecule. Achieving this clinical milestone further validates Coherus' development platform and demonstrates our ability to advance biosimilars across our portfolio," said Denny Lanfear, President and Chief Executive Officer of Coherus.

About Coherus BioSciences, Inc.
Coherus is a late-stage clinical biologics platform company focused on the global biosimilar market.  Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development.  Coherus' commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access.  For additional information, please visit www.coherus.com.

Coherus BioSciences Contact
Beth Jimison
(650) 649-3526
bjimison@coherus.com

Logo - http://photos.prnewswire.com/prnh/20120507/SF01448LOGO


'/>"/>
SOURCE Coherus BioSciences
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Coherus anuncia início do estudo Fase 3 do CHS-0214 (Biossimilar Investigativo do Etanercept) em psoríase crônica em placas (RaPsOdy)
2. Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis (RaPsOdy)
3. Coherus Biosciences Invited to Present at 2014 J.P. Morgan Annual Healthcare Conference
4. Coherus Biosciences als Präsentator zur J.P. Morgan Annual Healthcare Conference 2014 eingeladen
5. Coherus anuncia que CHS-0214 (biosimilar etanercept propuesto) supera punto final primario en decisivo estudio clínico farmacocinético
6. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
7. Echo Therapeutics, Inc. Announces Second Quarter 2014 Financial Results and Provides Business Update
8. Edison Nation Medical Announces Innovation Search To Improve Hazardous Waste Disposal in Hospitals & Healthcare Facilities
9. NW BIO ANNOUNCES PRICING OF $17.5 MILLION OFFERING OF CONVERTIBLE NOTES
10. Vermillion Announces Additions to Commercial Management Team
11. Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... The global  anxiety disorders and depression treatment market  is expected to reach ... worldwide is anticipated to drive the market growth in the coming years. Increasing ... in the recent years. Continue Reading ... ... ...
(Date:1/23/2017)... , Jan 23, 2017 NeuroVive Pharmaceutical ... has signed a preclinical collaboration agreement with the Children,s Hospital ... J. Falk , M.D., a US key opinion leader in ... ... will evaluate compounds from NeuroVive,s research program, NVP015, in certain ...
(Date:1/21/2017)... , Jan 20, 2017 Research ... Clinical Laboratory Testing Market By Type of Test (Tumor, Clinical ... & By Type of Diseases (Tuberculosis, Influenza, Cancer, HIV/AIDS etc.), ... ... attractive destination for healthcare services, market segments, especially clinical lab ...
Breaking Medicine Technology:
(Date:1/23/2017)... Atlanta, Georgia (PRWEB) , ... January 23, 2017 ... ... leader in providing high-quality general gynecological care and gynecological services for ... to providing personalized care for a wide variety of reproductive services from routine ...
(Date:1/23/2017)... VA (PRWEB) , ... January ... ... Nutrition Partnership (SNP) has launched online education programs and resources at seafoodnutrition.org/programs ... and nutritional benefits of a seafood-rich diet. These resources have been developed ...
(Date:1/23/2017)... ... ... Valentine’s Day is a time when many people celebrate romance and love by giving cards, ... for the ideal present, Atlanta-based Perimeter Plastic Surgery is offering a Valentine’s Day ... $200 and get $50 free. , “A lot of people just buy the more ...
(Date:1/22/2017)... (PRWEB) , ... January 22, 2017 , ... "Photo Cloud ... to create a beautiful 3D slideshow with complete ease," said Christina Austin - CEO ... browser to place in the FCPX timeline. Presets include scenes with one, ...
(Date:1/21/2017)... ... January 21, 2017 , ... Salveo for life, a ... bringing its product to the United States as part of its presence to expand ... years, Alcovit aims to reduce the productions of nasty toxins as a result of ...
Breaking Medicine News(10 mins):